文献速递浆细胞疾病造血干细胞移植与细胞治疗

独特型疫苗联合自体T细胞过继回输治疗多发性骨髓瘤的随机2期试验

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
PubMed 文献 · Blood · 2022-01-01

该随机2期试验在36例多发性骨髓瘤患者中比较单纯KLH疫苗与Id-KLH疫苗联合自体移植及疫苗特异性共刺激T细胞回输的疗效。Id-KLH组完全缓解率50%对30%(P=.22)、3年无进展生存率56%对59%(P=.32),差异均未达统计学意义;但Id-KLH组T细胞免疫重建基因变化更显著。

要点

  • 联合方案未观察到剂量限制性毒性。
  • 完全缓解率与3年PFS在两组间无统计学差异。
  • Id-KLH组CD4+和CD8+ T细胞免疫重建更显著。

核心结论

  • Id-KLH疫苗联合自体T细胞过继回输未显著改善完全缓解率或3年无进展生存,但诱导了更显著的T细胞免疫重建。

研究设计与样本

  • 随机2期试验纳入36例多发性骨髓瘤患者,KLH对照组20例、Id-KLH组16例,均接受自体移植及疫苗特异性共刺激T细胞回输和2次疫苗加强。

主要发现

  • 末次评估时KLH组6例(30%)、Id-KLH组8例(50%)达完全缓解(P=.22)。
  • 3年无进展生存率KLH组59%、Id-KLH组56%(P=.32)。
  • 594基因Nanostring nCounter面板显示Id-KLH组T细胞免疫重建基因较基线变化更大,上调激活、效应功能诱导和记忆CD8+ T细胞生成相关基因。
  • 两臂缓解患者均见T细胞激活相关基因上调,基线时所有患者CD8+ T细胞耗竭标志物表达较高。

关键数值与推荐

  • 完全缓解率:KLH组30%对Id-KLH组50%,P=.22。
  • 3年无进展生存率:KLH组59%对Id-KLH组56%,P=.32。
  • 未观察到剂量限制性毒性(36例)。

临床怎么用

  • 该联合免疫治疗策略安全性可接受,免疫重建数据支持进一步研究疫苗与过继免疫治疗。

局限性

  • 样本量小(36例),完全缓解率与PFS差异未达统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We hypothesized that combining adoptively transferred autologous T cells with a cancer vaccine strategy would enhance therapeutic efficacy by adding antimyeloma idiotype (Id)-keyhole limpet hemocyanin (KLH) vaccine to vaccine-specific costimulated T cells. In this randomized phase 2 trial, patients received either control (KLH only) or Id-KLH vaccine, autologous transplantation, vaccine-specific costimulated T cells expanded ex vivo, and 2 booster doses of assigned vaccine. In 36 patients (KLH, n = 20; Id-KLH, n = 16), no dose-limiting toxicity was seen. At last evaluation, 6 (30%) and 8 patients (50%) had achieved complete remission in KLH-only and Id-KLH arms, respectively (P = .22), and no difference in 3-year progression-free survival was observed (59% and 56%, respectively; P = .32). In a 594 Nanostring nCounter gene panel analyzed for immune reconstitution (IR), compared with patients receiving KLH only, there was a greater change in IR genes in T cells in those receiving Id-KLH relative to baseline. Specifically, upregulation of genes associated with activation, effector function induction, and memory CD8+ T-cell generation after Id-KLH but not after KLH control vaccination was observed. Similarly, in responding patients across both arms, upregulation of genes associated with T-cell activation was seen. At baseline, all patients had greater expression of CD8+ T-cell exhaustion markers. These changes were associated with functional Id-specific immune responses in a subset of patients receiving Id-KLH. In conclusion, in this combination immunotherapy approach, we observed significantly more robust IR in CD4+ and CD8+ T cells in the Id-KLH arm, supporting further investigation of vaccine and adoptive immunotherapy strategies. This trial was registered at www.clinicaltrials.gov as #NCT01426828.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Qazilbash MH, Saini NY, Cha SC, et al. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood. 2022. PMID: 34521108. doi:10.1182/blood.2020008493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。